Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

109.41 +0.80 (+0.74%)
Streaming Delayed Price Updated: 9:54 AM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,044,987
Open 108.31
Bid (Size) 109.40 (1)
Ask (Size) 109.43 (1)
Prev. Close 108.61
Today's Range 108.00 - 109.65
52wk Range 83.05 - 119.65
Shares Outstanding 2,531,374,696
Dividend Yield 2.38%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer
From Merck & Co., Inc.
Via Business Wire
The 3 Best Defensive Stocks to Buy in June 2023
With market and economic concerns rising, investors may find comfort targeting these ideas for the best defensive stocks to buy. 
Via InvestorPlace

Performance

YTD
-1.56%
-1.56%
1 Month
-7.58%
-7.58%
3 Month
+1.04%
+1.04%
6 Month
-0.62%
-0.62%
1 Year
+20.92%
+20.92%

More News

Read More
This Is What Whales Are Betting On Merck & Co
Via Benzinga
Pharmaceutical Giant Merck Challenges Inflation Reduction Act over Medicare Drug Pricing, Calls It 'Extortion'
Via Benzinga
Analyst Ratings for Merck & Co
Via Benzinga
Novocure's Cancer Treating Electric Fields Improves Survival In Lung Cancer Patients, But Stock Tumbles On Remaining Doubts
Via Benzinga
Merck Delivers First Legal Blow To Biden's Medicare Negotiation Plan, Calling It A 'Sham'
Via Investor's Business Daily
U.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients
From Merck & Co., Inc.
Via Business Wire
Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Moderna and Merck Report Significant Success in Investigational Skin Cancer Therapy, Cuts Risk Of Distant Metastasis Or Death By 65%
Via Benzinga
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma
Via ACCESSWIRE
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC
From Merck & Co., Inc.
Via Business Wire
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
From Merck & Co., Inc.
Via Business Wire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Via Investor's Business Daily
BioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer Treatment
Via Investor's Business Daily
3 Undervalued Dow Stocks to Buy Before Wall Street Does
Via InvestorPlace
Medtronic, Merck, Williams Companies And More: CNBC's 'Final Trades'
Via Benzinga
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
From Merck & Co., Inc.
Via Business Wire
7 Dividend Stocks to Buy (and Never Sell)
Via InvestorPlace
3 Innovative Growth Stocks to Buy for Next-Gen Profits
Via InvestorPlace
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
Via Talk Markets
Nvidia Becomes Ninth Company To Hit $1 Trillion Market Cap — Who Could Be Next To Join Elusive Club?
Via Benzinga
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
Via MarketBeat
Topics Death
Exposures Death Product Safety
Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years
Via The Motley Fool
Arcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug Class
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.